Quoin Pharmaceuticals, Ltd. (QNRX) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
QNRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
QNRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export QNRX earnings history in CSV or JSON format
Free sign-in required to download data
Quoin Pharmaceuticals, Ltd. (QNRX) Earnings Overview
As of May 8, 2026, Quoin Pharmaceuticals, Ltd. (QNRX) reported trailing twelve-month net income of -$15.81B, reflecting -22033.5% year-over-year growth. The company earned $-5583.19 per diluted share over the past four quarters.
Looking at the long-term picture, QNRX's historical earnings data spans multiple years. The company achieved its highest annual net income of $15M in fiscal 2016.
Quoin Pharmaceuticals, Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), PTCT (-$187M net income, 39.4% margin), QNRX has comparable earnings metrics. Compare QNRX vs RARE →
QNRX Earnings vs Peers
Earnings metrics vs comparable public companies
QNRX Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$15.80B | -176242.6% | -$16M | $-14796.26 | - | - |
| 2024 | -$9M | -3.2% | -$10M | $-66.85 | - | - |
| 2023 | -$9M | +7.4% | -$9M | $-337.47 | - | - |
| 2022 | -$9M | +56.3% | -$9M | $-22.97 | - | - |
| 2021 | -$21M | -924.3% | -$6M | $-28543.20 | - | - |
| 2020 | -$2M | -34.3% | -$2M | $-88.10 | - | - |
| 2019 | -$2M | -110.2% | -$2M | $-440.29 | - | - |
| 2018 | $15M | +50.6% | $15M | $7100.73 | - | - |
| 2017 | $10M | -33.6% | $10M | $5450.81 | - | - |
| 2016 | $15M | +685.1% | $15M | $10084.00 | - | - |
See QNRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs QNRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare QNRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonQNRX — Frequently Asked Questions
Quick answers to the most common questions about buying QNRX stock.
Is QNRX growing earnings?
QNRX EPS fell to $-5583.19, with earnings declining -22033.5%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-15.8B.
What are QNRX's profit margins?
Quoin Pharmaceuticals, Ltd. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are QNRX's earnings?
QNRX earnings data spans 2015-2025. The declining earnings trend is -22033.5% YoY. Historical data enables comparison across business cycles.